Drug profile · INN
bevacizumab
ABEVMY
bevacizumab (ABEVMY) is a vascular endothelial growth factor a inhibitor. Associated with Amgen. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — bevacizumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INTRAVENOUS
- Patents
- 20
- Programs
- 132
- Data quality
- 0.89
Quick answer
bevacizumab (ABEVMY) is a vascular endothelial growth factor a inhibitor. Associated with Amgen. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor A inhibitor
Primary target: Vascular endothelial growth factor A, long form
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review
Outlook Therapeutics has resubmitted its Biologics License Application (BLA) for LYTENAVA (bevacizumab-vikg) to the FDA, initiating a 60-day Class 1 review. This marks a critical step for the drug's potential approval in treating neovascular age-related macular degeneration (nAMD).
This Week’s Biopharma News: New Approvals, Appeals, and AI
This week's biopharma news highlights significant FDA approvals for Datroway and Hepcludex, a key appeal win for Outlook regarding bevacizumab, and promising Phase 3 data for BioMarin's VOXZOGO. The evolving landscape also sees increased integration of AI in drug development and regulatory processes.
Biosimilar Market Growth India: Key Drivers, Challenges & Opportunities
The biosimilar market in India is poised for significant growth, driven by increasing demand for affordable biologics like Trastuzumab, alongside various challenges and opportunities.
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2026039538
MÉTHODES DE TRAITEMENT DE TUMEURS PANCRÉATIQUES EXPRIMANT CERTAINS BIOMARQUEURS
granted -
WO 2025230528
MÉTHODES DE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE
granted -
US 2025250277
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
granted -
WO 2025147499
LUTIKIZUMAB DESTINÉ À ÊTRE UTILISÉ DANS UN TRAITEMENT DE L'HIDRADÉNITE SUPPURÉE
granted -
EP 4563165
PSMA-STEAP1-IMMUNGLOBULIN (DVD-IG)-MOLEKÜLE MIT ZWEIFACH VARIABLER DOMÄNE UND ARZNEIMITTELKONJUGATE
granted -
US 2025059280
METHODS OF TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
granted -
US 2025057837
Methods for Treating HCV
granted -
US 2025049789
METHODS OF TREATING ALOPECIA ARAETA
granted -
US 2025034157
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
granted -
US 11542526
Oncolytic adenoviral vector and methods of use
granted -
US 10167452
Viral purification methods
granted -
US 9523691
Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis
granted -
US 8685734
Viral purification methods
granted -
US 8183204
Methods and compositions for increasing skin remodeling
granted -
US 7906535
High concentration topical insecticides containing pyrethroids
granted -
US 7901921
Viral purification methods
granted -
US 7429485
Method of producing infectious reovirus
granted -
US 7223585
Viral purification methods
granted -
US 7186542
Method of extracting virus from cell culture
granted -
US 7049127
Method of producing infectious reovirus
expired
Frequently asked questions
What is bevacizumab?
bevacizumab (ABEVMY) is a vascular endothelial growth factor a inhibitor. Associated with Amgen. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for bevacizumab?
ABEVMY is a marketed brand name for bevacizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bevacizumab?
bevacizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.